[PDF][PDF] Integrative clinical genomics of advanced prostate cancer

D Robinson, EM Van Allen, YM Wu, N Schultz… - Cell, 2015 - cell.com
Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

GM Frampton, A Fichtenholtz, GA Otto, K Wang… - Nature …, 2013 - nature.com
As more clinically relevant cancer genes are identified, comprehensive diagnostic
approaches are needed to match patients to therapies, raising the challenge of optimization …

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

CE Barbieri, SC Baca, MS Lawrence, F Demichelis… - Nature …, 2012 - nature.com
Prostate cancer is the second most common cancer in men worldwide and causes over
250,000 deaths each year. Overtreatment of indolent disease also results in significant …

[PDF][PDF] Organoid cultures derived from patients with advanced prostate cancer

D Gao, I Vela, A Sboner, PJ Iaquinta, WR Karthaus… - Cell, 2014 - cell.com
The lack of in vitro prostate cancer models that recapitulate the diversity of human prostate
cancer has hampered progress in understanding disease pathogenesis and therapy …

[HTML][HTML] Punctuated evolution of prostate cancer genomes

SC Baca, D Prandi, MS Lawrence, JM Mosquera… - Cell, 2013 - cell.com
The analysis of exonic DNA from prostate cancers has identified recurrently mutated genes,
but the spectrum of genome-wide alterations has not been profiled extensively in this …

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

H Beltran, D Prandi, JM Mosquera, M Benelli, L Puca… - Nature medicine, 2016 - nature.com
An increasingly recognized resistance mechanism to androgen receptor (AR)-directed
therapy in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low …

Genomic correlates of clinical outcome in advanced prostate cancer

W Abida, J Cyrta, G Heller, D Prandi… - Proceedings of the …, 2019 - National Acad Sciences
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …

Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine

C Pauli, BD Hopkins, D Prandi, R Shaw, T Fedrizzi… - Cancer discovery, 2017 - AACR
Precision medicine is an approach that takes into account the influence of individuals'
genes, environment, and lifestyle exposures to tailor interventions. Here, we describe the …

Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing

DR Robinson, YM Wu, S Kalyana-Sundaram, X Cao… - Nature …, 2013 - nature.com
A 44-year old woman with recurrent solitary fibrous tumor (SFT)/hemangiopericytoma was
enrolled in a clinical sequencing program including whole-exome and transcriptome …

TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

F Demichelis, K Fall, S Perner, O Andrén, F Schmidt… - Oncogene, 2007 - nature.com
The identification of the TMPRSS2: ERG fusion in prostate cancer suggests that distinct
molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2 …